IDYA
IDEAYA Biosciences, Inc.−$0.31 (0.98%) At close $31.33 · Today
☾After Hours −$0.06 (0.21%) Nov 3, 7:59 PM ET
About IDYA
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Company
- Headquarters
- South San Francisco, CA
- Employees
- 145 (2026)
- Listed
- May 23, 2019
- Exchange
- Nasdaq
- Website
- ideayabio.com
- SEC industry
- Pharmaceutical Preparations
- Cylvex sector
- Health Care · Pharmaceuticals
Pharmaceuticals
- Market cap #68 of 430
- P/B #146 of 396
Ranked highest first among stocks Cylvex covers.
- LLYEli Lilly and Company$1.26T-0.11%
- JNJJohnson & Johnson$640.8B-1.62%
- ABBVAbbVie Inc$505.4B-0.98%
- MRKMerck & Co Inc$356.9B-2.49%
- NVSNovartis AG$300.8B-1.40%
Financial summary
Related companies
About
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
From company filings and market data · Not investment advice
Price data
52W range and average volume from daily bars (unadjusted, last 252 sessions).
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.